Novamed In-Licenses Products from Iroko and EUSA To Strengthen Cardiovascular And Oncology Pipeline
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - NovaMed Pharmaceuticals announced July 10 it has reached agreements with U.S.-based Iroko and U.K. firm EUSA Pharma to in-license Iroko's cardiovascular drugAggrastat (tirofiban) and EUSA's oncology drug Erwinase (crisantaspase)
You may also be interested in...
China's Outsource Sales Model Takes A Big Step: SciClone Takes Out NovaMed
SciClone Pharmaceuticals will significantly broaden its commercial footprint across China by acquiring privately owned, Shanghai-based specialty pharma NovaMed Pharmaceuticals for close to $62 million plus potential earnouts in a deal that closed April 18
China's Outsource Sales Model Takes A Big Step: SciClone Takes Out NovaMed
SciClone Pharmaceuticals will significantly broaden its commercial footprint across China by acquiring privately owned, Shanghai-based specialty pharma NovaMed Pharmaceuticals for close to $62 million plus potential earnouts in a deal that closed April 18
EUSA Finds Japanese Partner For Lead Product In Generics-turned-innovator Ohara
TOKYO - In-licensing firm EUSA Pharma established its first partnership in Japan, behind similar deals in South Korea and China, for its acute lymphoblastic leukemia treatment Erwinase (erwinia L-asparaginase)